EMMELINE KATSARELIS: Open Payments
NPI 1013496538 · STANFORD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,825 in 29 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $172 · 2025 $1,825
Food & beverage: $1,735Education: $90
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 16 | $1,109 |
| AstraZeneca Pharmaceuticals LP | 6 | $474 |
| SANOFI-AVENTIS U.S. LLC | 1 | $90 |
| GENZYME CORPORATION | 2 | $51 |
| HARMONY BIOSCIENCES LLC | 1 | $34 |
| Verona Pharma, Inc. | 1 | $25 |
| Merck Sharp & Dohme LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
Products named: OFEV, BREZTRI, FASENRA, DUPIXENT, JASCAYD, WAKIX, Ohtuvayre, ZERBAXA.
Industry payments across CA — which companies pay providers there.
